COMPOSITION FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE PRINCIPLES IN GYNAECOLOGIC AND RECTAL FIELD AND USES THEREOF

Abstract

The present invention relates to a composition for the administration of biologically active substances in a gynaecologic and rectal ambit, as well as the uses of said composition. Said composition presents particularly favourable technological and stability characteristics of the end product, above all with regard to the viscosity after the dissolution/resuspension of the same in a hydrophilic liquid medium which allows a better adhesion and a direct contact from bacteria to the treated mucosae. Said composition includes a specific viscosizing agent selected from the group of the gums, which can play an important prebiotic function by contributing in a significant way to the correct growth and colonization of the probiotic culture, thus forming a perfect symbiotic system.

Description

The present invention relates to a composition for the administration of biologically active substances in a gynaecologic and rectal ambit, as well as the uses of said composition. Said composition presents particularly favourable technological and stability characteristics of the end product, above all as for the viscosity after the dissolution/resuspension of the same in a hydrophilic liquid medium which allows a better adhesion and a direct contact from bacteria to the treated mucosae. Said composition includes a specific viscosizing agent selected from the group of rubbers, which can play an important prebiotic function by contributing in a significant way to the correct growth and colonization of the probiotic culture, thus forming a perfect symbiotic system.

It is known that the compositions intended for the rectal or vaginal administration must have peculiar characteristics which are able to average a balanced and quantitatively correct delivery of the biologically active substance contained in said compositions.

Most of the compositions, although having a varying water content, are however in a solid form, and are delivered as such.

In this case, the delivery of the biologically active substance can occur by melting, at the body temperature, of the whole components of the composition, or by dissolution or dispersion of said components in the vaginal secretion or in the liquid present in the rectum.

However, there are some cases in which the compositions above mentioned are introduced in the destination site in a liquid form, as a solution or dispersed system.

In this case, the composition may directly be in a liquid form, or it is necessary the addition of the composition itself to an adequate volume of liquid before the administration.

The presence of a biologically active substance in a composition with the characteristics above described, is often problematic, as the effectiveness of the same, after the rectal or vaginal introduction of a suspension or solution, tends to be limited over time. In fact, as most of the liquid administered tends to be discharged more or less quickly from the application seat, the effective contact time of said biologically active substance with the rectal or vaginal mucosa is sensibly reduced.

The use of a viscous formulation with an oily-hydrophobic base also presents some drawbacks. In fact, although it ensures a higher residence time of the active substance, for example a probiotic microorganism, it physically prevents the contact thereof since the oily-hydrophobic matrix forms an insulating film which avoids its direct contact with the treated mucosa.

In view of what above described, the residual quantity of biologically active substance remaining within the rectal or vaginal space is almost always insufficient to ensure a real effectiveness of the same, both when the action is carried out at a local level (like in most of the vaginal administrations) and when a good systemic absorption of the biologically active substance is desired (like in some typologies of rectal administrations).

The best current solution for the rectal or vaginal transport of biologically active substances is the administration of a composition in a solid form, which however has a more or less remarkable content of water or other liquid.

However, not all the biologically active substances can be introduced in solid compositions for rectal or vaginal purposes, to be introduced as such in the human body, as the quantity of water existing therein, often high, promotes the degradation thereof or however a more or less considerable chemical-physical alteration, in relatively short times.

Because of this, the time elapsing between the industrial preparation of the composition and the administration of the same is almost always the cause of a remarkable reduction of the effective titer of said active substance, up to levels often completely insufficient if compared to those typical of the therapeutic window.

A specific kind of biologically active substance, represented by the group including living microorganisms is noteworthy, with a particular reference to those with a probiotic and symbiotic valence.

In particular, the rectal administration of probiotic microorganisms presents, with respect to the oral one, the advantage that said microorganisms are not required to overcome the triple barrier (represented by the gastric juice, the bile secretion and the pancreatic one) and therefore are not subjected to unavoidable reductions, more or less remarkable, of their titer before reaching the intestine.

The best mode for storing said microorganisms until the time of administration, however, is in an anhydrous form, for example within a powdered formulation to be joined to a proper volume of liquid which is then capable of ensuring an effective and concrete transport of the microorganisms in the rectal or vaginal space.

The effectiveness of such composition is connected to the persistence, within the body space in question, of the probiotic microorganisms for sufficient times for expressing their clinical-healthy effect.

An effective persistence of said microorganisms would therefore lead to their actual integration within the intestinal and/or vaginal microflora, with a consequent ability of conducting in an advantageous way the metabolic and, more generally, the microbiologically manifested activity by said microflora.

In each case, it is not possible, at present, to assure a valid persistence of the probiotic microorganisms within the rectal and/or vaginal space after the administration of a composition with the characteristics above described, as the rapid discharging from the organism of the transport liquid of said microorganisms or their insulation in a oily-hydrophobic matrix would cause most of them to not have the time of colonizing the mucosa, with a consequent reduced effectiveness of said formulation.

Therefore, there remains the need of being able to provide a composition in a solid form for an effective rectal and/or vaginal administration, after suspension or dissolution of the same in a proper hydrophilic liquid medium, of biologically active substances.

In particular, there remains the need of being able to provide a composition for the rectal and/or vaginal administration of biologically active substances, in particular microorganisms with a probiotic or symbiotic valence, which combine the characteristic of an actual and adequate stability of said substances within the composition itself with a concrete effectiveness of the composition during the administration. It is an object of the present invention to give an adequate answer to the need above pointed out.

This and other aims, which will result apparent from the following detailed description, have been attained by the Applicant which has unexpectedly found that, through the use of a proper quantity of at least a proper hydrophilic viscosizing agent, it is possible to prepare a composition for the rectal or vaginal administration of biologically active substances (preferably including microorganisms with a probiotic or symbiotic valence), capable of meeting the need above pointed out.

Said composition is in a solid form, advantageously in an anhydrous form. The composition is diluted before the administration, with a proper quantity of water or other physiologically compatible hydrophilic liquid medium.

In this way, a suspension or solution with such technological peculiarities to ensure the concrete transport of said substances within the body space of interest is obtained, as well as, above all, their persistence within the same and the direct contact with the treated mucosa.

Said technological peculiarities then allow an effective beneficial action of the composition, both when the biological action is manifested at a local level, and when it is necessary the systemic absorption of the substances themselves.

Therefore, a subject of the present invention is a composition for the rectal or vaginal administration of biologically active substances having the characteristics reported in the appended independent claim. Moreover, the uses of said composition in medicine and, in particular, in the gynaecologic or rectal ambit form another object of the present invention, as reported in the appended claims.

Preferred embodiments of the present invention are reported in the appended dependent claims.

Features and advantages of the present invention are pointed out in detail in the following description; moreover, they are further shown, by way of example, also within the enclosed Charts 1-4 and Tables 1-4, wherein:

• • chart 1 shows the course ,over time, of the viscosity of a solution or suspension, kept at 25° C., obtained by addition of a composition according to the invention, including tara gum as a viscosizing agent and Lactobacillus paracasei as a biologically active substance, to 20 ml of water; the viscosity has been measured by using a rotational viscometer, or rotoviscometer, with a SpR3 rotor and with an angular speed of 50 rpm, starting from the time of the resuspension/dissolution until the following 35 minutes, and is expressed in mPa·second (corresponding to 1 centipoise, cP); in this case the viscosizing agent is present at 0.9% (weight of the viscosizing agent/volume of resuspension or dissolution liquid, w/v);
  • chart 2 shows the course over time of the viscosity of a solution or suspension, maintained at 38° C., through addition of the component used in the experiment of the chart 1 to 20 ml of water; the viscosity has been measured according to the same procedures of the chart 1; the viscosizing agent is present at 0.90 (w/v);
  • chart 3 shows the course over time of the pH of 15 ml of a culture medium inoculated with 1% (v/v) of a L. rhamnosus in which the carbon and the energy sources are given by a guar gum. The pH measurements have been conducted from the time of the inoculum up to 24 hours from the inoculum. The positive control is given from a glucose containing medium. The negative control is given from a medium completely free of carbon and energy sources;
  • chart 4 shows the course, over time, of the pH of 15 ml of a culture medium inoculated with 1% (v/v) of a B. breve in which the carbon and energy sources are given by a tara gum. The pH measurements have been conducted from the time of the inoculum up to 27 hours from the inoculum. The positive control is given from a glucose containing medium. The negative control is given from a medium completely free of carbon and energy sources;
  • table 1 shows the viscosity values which have originated the chart 1;
  • table 2 shows the viscosity values which have originated the chart 2;
  • table 3 shows the pH values which have originated the chart 3;
  • table 4 shows the pH values which have originated the chart 3.

The Applicant has found that, by introducing at least an opportune viscosizing agent in a composition, intended for the rectal or vaginal administration of at least a biologically active substance, it is possible to obtain, after resuspension or dissolution of said composition in an opportune volume of a physiologically compatible hydrophilic liquid medium, a viscosity of said liquid which is particularly suitable for the purpose above described and stable over time for a few hours.

In particular, said viscosity presents a peculiar course over time, by attesting on relatively low values in the times immediately after the dissolution/suspension of a composition according to the present invention and such to easily allow the suction of said liquid in an opportune cannula for the rectal and/or vaginal application, as well as pouring or mixing the same with other opportune components in a liquid or solid form.

With the passing of time, however, the tixotropic characteristics of the above suspension/solution cause the occurrence of a gradual increase of the viscosity. If the composition is adequately formulated the viscosity value does not reach excessive values, but such to allow a valid residence, in the intestinal or vaginal lumen, of the active substance existing therein for a sufficient number of hours, to ensure the colonization from the probiotic bacteria.

In an embodiment of the invention, the viscosizing agent of a composition according to the invention is selected from the group including polymers containing, in their structure, hydroxy and/or carboxy groups, such as starch, modified starches, seed flours (such as locust beam and others), agar-agar, cellulose derivatives, gelatine, carrageenans, alginic acid, alginates and other adequate polymers, or mixtures thereof.

In a preferred embodiment, said agent is selected from the group including soluble food fibers, such as pectins, gums, depolymerized gums, galactomannans, glucomannans, or mixtures thereof; preferably, said fibers are represented by at least a gum.

In a particularly preferred embodiment, said gum is selected from the group including; guar gum, tara gum, xantharean gum, xanthan gum, konjac gum, karaya gum, tragacanth, acacia, gellan gum and other gums particularly suitable for the purpose, or a mixture thereof. In a particularly preferred embodiment, the viscosizing agent is selected from the group including; calcium alginate and/or tara gum and/or carrageenan and/or guar gum.

Preferably, the above viscosizing agent is added to a composition such that, after dissolution/resuspension in water or other proper liquid medium (generally called formulation), its percentage is ≧0.05% (w/v); advantageously, said percentage is between 0.2 and 20% (w/v), preferably from 0.4 to 5% (w/v); particularly preferred, said percentage is between 0.7 and 3% (w/v).

Said percentage is varying as a function of the specific viscosizing agent used and the physical-chemical peculiarities thereof, above all as for the tixotropic characteristics of the same when dissolved/resuspended in water or other proper liquid medium.

By mere way of absolutely not limiting example, there are reported three compositions in which the viscosizing agent is selected according to the criteria above stated, to be suspended/dissolved in 100 ml of water before the administration.

Composition 1
	Biologically active substance/s	200	mg
	Guar gum	1.2	g
	Excipients	1.6	g

Composition 2
	Biologically active substance/s	250	mg
	Tara gum	1.1	g
	Excipients	1.85	g

Composition 3
	Biologically active substance/s	150	mg
	Calcium alginate	0.8	g
	Excipients	1.25	g

Preferably, said compositions are formulated such that, after the dissolution/resuspension in an adequate volume of a liquid medium, they result isotonic if compared with the vaginal liquid or the rectal one. The pH of the solution/suspension obtained is generally between 0.5 and 8.5, preferably from 6.0 to 8.0, if said solution/suspension is intended for the introduction in the rectum, while it is generally between 3.5 and 7.0, preferably from 4.0 to 5.5 if said solution/suspension is intended for the introduction in the vaginal space.

By way of example, resuspension/dissolution volumes of a composition according to the invention, intended for the introduction within the rectum are generally ≧5 ml; preferably, between 8 and 70 ml, advantageously from 10 to 55 ml; particularly preferred, between 12 and 40 ml. Resuspension/dissolution volumes of a composition according to the invention, intended for the introduction within the vaginal space are generally ≧1 ml; preferably, between 1.5 and 10 ml, advantageously from 2 to 8 ml; particularly preferred, between 3 and 7 ml. Advantageously, said composition for vaginal purposes can also have a detergent purpose; in this case, resuspension volumes are generally ≧10 ml, preferably between 20 and 150 ml; particularly preferred, between 40 and 120 ml.

In a preferred embodiment of the invention, the biologically active substance of a composition according to the invention is selected from the group including living microorganisms physiologically compatible with the human body.

Preferably, said microorganisms are selected from the microorganisms group having a probiotic or symbiotic valence.

More preferably, said microorganisms with a probiotic valence are selected from the microbial group including the genera: Bifidobacterium, Lactobacillus, Leuconostoc, Lactococcus, Streptococcus, Pediococcus, Propionibacterium, Bacillus, Enterococcus, Saccharomyces.

For example, of the genus Lactobacillus the species: L. pentosus, L. plantarum, L. caseissp. casei, L. casei ssp. paracasei, L. rhamnosus, L. acidophilus, L. delbrueckii ssp. bulgaricus, L. delbrueckii ssp. lactis, L. fermentum, L. gasseri have found use.

For example, of the genus Bifidobacterium the species: B. longum, B. breve, B. bifidum, B. animalis, B. animalis ssp. lactis, B. adolescentis, B. pseudocatenulatum, B. catenulatum, B. infantis have found use.

For example, of the genus Lactococcus the species: L. lactis and L. lactis ssp. Lactis have found use. For example, of the genus Streptococcus the species S. thermophilus has found use.

In a preferred embodiment of the invention, the composition includes from one to six strains, preferably four strains; advantageously, at least two bacterial probiotic strains selected from those above mentioned. In the table 5, by way of example, a group of microorganisms which find a valid application in the context of the present invention is reported.

All strains have been deposited according to the Budapest Treaty and are accessible to the public on request to the competent deposit Authority.

The composition according to the present invention finds a valid application for the preparation of a pharmaceutical formulation for the preventive and/or curative treatment of the rectum and the vagina; in particular, for the treatment of the infective pathologies of the rectum and the vagina by rectally or vaginally internal administration.

In another preferred embodiment of the invention, said at least one probiotic microorganism is added to a composition according to the invention, which also includes at least a prebiotic fiber, thus obtaining a symbiotic composition.

Said at least one prebiotic fiber is a molecule of a saccharide, generally oligo- or polysaccharide nature, usually soluble or at least partly soluble in water or in an aqueous solution where it can be used as a carbon and/or energy source from one or more probiotic microbial species having the required enzymatic complement for the hydrolysis of said fiber and for the consequent release of the constituting monosaccharide units.

Preferably, said prebiotic fiber is selected from the group including: fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), trans-galacto-oligosaccharides (TOS), xylo-oligosaccharides (XOS), chitosan-oligosaccharides (COS), α-galactoside (such as raffinose, stachyose and so on), pectins, gums, partly hydrolized gums, inulin, psyllium, arabinogalactans, acacia, locust bean, oat, bamboo fibers, citrus fibers and, generally, fibers containing a soluble and an insoluble portions, in a varying ratio therebetween.

In a particularly preferred embodiment of the invention, the composition includes a mixture of two or more prebiotic fibers selected from those above mentioned.

The Applicant has found particularly advantageous the introduction of at least one prebiotic fiber to a composition having the features according to the present invention, intended for the rectal or vaginal administration of at least a probiotic microorganism, since above all the rectal environment is particularly poor from the point of view of the carbon and/or energy sources for the bacterial metabolism.

Advantageously, said prebiotic fiber can per se contribute, at least partly, to impart suitable viscosity characteristics, over time, to the suspension/solution intended for the introduction within the rectal or vaginal space, according to what has been above described.

In a preferred embodiment, the viscosizing agent in form of gum can play, in addition to its technological function above described, also an important prebiotic function by contributing in a significant way to the correct growth and colonization of the probiotic culture, thus forming a perfect symbiotic system.

In fact, in the experimental example reported in the Chart 3, table 3, it can be seen that a microorganism of the genus Lactobacillus rhamnosus is capable of using a gum, for example guar gum, as a prebiotic.

Whereas, in the experimental example reported in the Chart 4, table 4, it can be seen that a microorganism of the genus Bifidobacterium breve is capable of using a gum, for example the tara gum, as a prebiotic.

As a not limiting example, there are reported two compositions according to the particularly preferred embodiments of the present invention intended for the rectal introduction, considering 20 ml as a dissolution/resuspension volume of the composition itself.

Composition 1
	Lactobacillus rhamnosus	25 109	CFU
	Inulin	0.80	g
	Guar gum	0.15	g
	Calcium alginate	0.10	g
	Sodium chloride	0.10	g
	Magnesium citrate	0.08	g

Composizione 2
	Bifidobacterium animalis ssp. lactis	20 · 109	CFU
	Fructo-oligosaccharides (FOS)	0.40	g
	Inulin	0.40	g
	Tara gum	0.18	g
	Sodium chloride	0.15	g
	Calcium carbonate	0.02	g
	Hydroxypropylmethyl cellulose (HPMC)	0.11	g

By additional way of example, there are reported three compositions according to the particularly preferred embodiments of the present invention intended for the vaginal introduction, considering 4 ml as a dissolution/resuspension volume of the composition 3 and 80 ml as a dissolution/resuspension volume of the compositions 4 and 5.

Composition 3
	Lactobacillus fermentum	20 · 109	CFU
	Arabinogalactan	0.40	g
	Galacto-oligosaccharides (GOS)	0.40	g
	Tara gum	0.05	g
	Sodium chloride	0.025	g
	Citric acid	0.005	g
	Microcrystalline cellulose	0.03	g

Composition 4
	Lactobacillus paracasei	25 · 109	CFU
	Glucomannan	0.90	g
	Sodium chloride	0.45	g
	Citric acid	0.04	g
	Hydroxypropyl cellulose (HPC)	0.48	g

Composition 5
	Bifidobacterium breve	20 · 109	CFU
	Fructo-oligosaccharides (FOS)	0.40	g
	Inulin	0.40	g
	Tara gum	1.0	g
	Sodium chloride	0.45	g
	Hydroxypropylmethyl cellulose (HPMC)	0.40	g

Preferably, the isotonic feature of said compositions, after dissolution/resuspension in the volume of used liquid, is assured with at least an excipient, generally a salt, selected from the group including the ions: chloride, iodide, carbonate in its mono- and dibasic forms, phosphate in its mono-, di- and tribasic forms, sulfate in its mono- and dibasic forms, nitrate, citrate, oxalate, gluconate, tartrate, lactate, acetate or mixtures thereof.

The cationic part of the salts above mentioned is generally selected from the group of ions including: sodium, calcium, magnesium, potassium, ammonium, manganese, copper, zinc, cobalt, iron ions or an opportune mixture of the same.

By additional way of example, in the compositions according to the present invention, one or more components selected from the group including: starches, modified starches, celluloses, hemicelluloses, modified celluloses, such as microcrystalline cellulose, hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxypropylethyl cellulose (HPEC), methylcellulose, ethylcellulose, propylcellulose and other proper polymers, or opportune mixtures thereof, can be further additioned.

TABLE 1
25° C.
           viscosity
time, min. (mPa · s)
2          1
4          50
5          90
7          240
10         620
15         1075
20         1220
25         1220
30         1225
35         1230

TABLE 2
38° C.
           viscosity
time, min. (mPa · s)
2          70
4          200
5          340
7          550
10         770
15         1010
20         1150
25         1240
30         1255
35         1270

	TABLE 3
	time
	0	1	2	3	5	6	7	8	24
MRS + glucose	6.73	6.66	6.50	6.33	5.00	4.45	4.23	4.06	3.67
(positive control)
MRS + guar gum	6.73	6.66	6.65	6.64	6.53	6.44	6.27	6.23	6.08
base MRS	6.73	6.73	6.69	6.69	6.68	6.68	6.68	6.68	6.59
(negative control)

	TABLE 4
	time
	0	2	3	4	5	6	7	8	9	23	24	26	27
MRS + glucose	6.73	5.62	5.26	5.04	4.89	4.79	4.70	4.64	4.60	4.38	4.36	4.31	4.29
(positive control)
MRS + tara gum	6.73	6.51	6.43	6.38	6.35	6.34	6.33	6.31	6.29	5.84	5.79	5.75	5.74
base MRS	6.73	6.71	6.69	6.68	6.68	6.68	6.68	6.68	6.68	6.61	6.59	6.57	6.56
(negative control)

TABLE 5
		Deposit	Date of
No.	Name	number	deposit	Applicant
1	Streptococcus	LMG P-18383	May 5, 1998	ANIDRAL S.R.L.
	thermophilus
2	Streptococcus	LMG P-18384	May 5, 1998	ANIDRAL S.R.L.
	thermophilus
3	Lactobacillus	LMG P-21019	Oct. 16, 2001	MOFIN S.R.L.
	pentosus
4	Lactobacillus	LMG P-21020	Oct. 16, 2001	MOFIN S.R.L.
	plantarum
5	Lactobacillus	LMG P-21021	Oct. 16, 2001	MOFIN S.R.L.
	plantarum
6	Lactobacillus	LMG P-21022	Oct. 16, 2001	MOFIN S.R.L.
	plantarum
7	Lactobacillus	LMG P-21023	Oct. 16, 2001	MOFIN S.R.L.
	plantarum
8	Lactobacillus casei	LMG P-21380	Jan. 31, 2002	ANIDRAL S.R.L.
	ssp. paracasei
9	Lactobacillus	LMG P-21381	Jan. 31, 2002	ANIDRAL S.R.L.
	belonging to the
	acidophilus group
10	Bifidobacterium	LMG P-21382	Jan. 31, 2002	ANIDRAL S.R.L.
	longum
11	Bifidobacterium	LMG P-21383	Jan. 31, 2002	ANIDRAL S.R.L.
	breve
12	Bifidobacterium	LMG P-21384	Jan. 31, 2002	ANIDRAL S.R.L.
	lactis
13	Lactobacillus	LMG P-21385	Jan. 31, 2002	MOFIN S.R.L.
	plantarum
14	Lactococcus lactis	LMG P-21387	Mar. 15, 2002	MOFIN S.R.L.
	ssp. lactis
15	Lactococcus lactis	LMG P-21388	Jan. 31, 2002	MOFIN S.R.L.
	ssp. lactis
16	Lactobacillus	LMG P-21389	Mar. 15, 2002	MOFIN S.R.L.
	plantarum
17	Streptococcus	DSM 16506	Jun. 18, 2004	ANIDRAL S.R.L.
	thermophilus
18	Streptococcus	DSM 16507	Jun. 18, 2004	ANIDRAL S.R.L.
	thermophilus
19	Bifidobacterium	DSM 16603	Jul. 20, 2004	ANIDRAL S.R.L.
	longum
20	Bifidobacterium	DSM 16604	Jul. 20, 2004	ANIDRAL S.R.L.
	breve
21	Lactobacillus casei	DSM 16605	Jul. 20, 2004	ANIDRAL S.R.L.
	ssp. rhamnosus
22	Lactobacillus	DSM 16606	Jul. 20, 2004	ANIDRAL S.R.L.
	delbrueckii ssp.
	bulgaricus
23	Lactobacillus	DSM 16607	Jul. 20, 2004	ANIDRAL S.R.L.
	delbrueckii
	ssp. bulgaricus
24	Streptococcus	DSM 16590	Jul. 20, 2004	ANIDRAL S.R.L.
	thermophilus
25	Streptococcus	DSM 16591	Jul. 20, 2004	ANIDRAL S.R.L.
	thermophilus
26	Streptococcus	DSM 16592	Jul. 20, 2004	ANIDRAL S.R.L.
	thermophilus
27	Streptococcus	DSM 16593	Jul. 20, 2004	ANIDRAL S.R.L.
	thermophilus
28	Bifidobacterium	DSM 16594	Jul. 21, 2004	ANIDRAL S.R.L.
	adolescentis
29	Bifidobacterium	DSM 16595	Jul. 21, 2004	ANIDRAL S.R.L.
	adolescentis
30	Bifidobacterium	DSM 16596	Jul. 21, 2004	ANIDRAL S.R.L.
	breve
31	Bifidobacterium	DSM 16597	Jul. 21, 2004	ANIDRAL S.R.L.
	pseudocatenulatum
32	Bifidobacterium	DSM 16598	Jul. 21, 2004	ANIDRAL S.R.L.
	pseudocatenulatum
33	Staphylococcus	DSM 17102	Feb. 01, 2005	ANIDRAL S.R.L.
	xylosus
34	Bifidobacterium	DSM 17103	Feb. 01, 2005	ANIDRAL S.R.L.
	adolescentis
35	Lactobacillus	DSM 17104	Feb. 01, 2005	ANIDRAL S.R.L.
	plantarum
36	Streptococcus	DSM 17843	Dec. 21, 2005	ANIDRAL S.R.L.
	thermophilus
37	Streptococcus	DSM 17844	Dec. 21, 2005	ANIDRAL S.R.L.
	thermophilus
38	Streptococcus	DSM 17845	Dec. 21, 2005	ANIDRAL S.R.L.
	thermophilus
39	Lactobacillus	DSM 18295	May 24, 2006	ANIDRAL S.R.L.
	fermentum
40	Lactobacillus	DSM 18296	May 24, 2006	ANIDRAL S.R.L.
	fermentum
41	Lactobacillus	DSM 18297	May 24, 2006	ANIDRAL S.R.L.
	fermentum
42	Lactobacillus	DSM 18298	May 24, 2006	ANIDRAL S.R.L.
	fermentum
43	Lactobacillus	DSM 18299	May 24, 2006	ANIDRAL S.R.L.
	gasseri
44	Lactobacillus	DSM 18300	May 24, 2006	ANIDRAL S.R.L.
	gasseri
45	Lactobacillus	DSM 18301	May 24, 2006	ANIDRAL S.R.L.
	gasseri
46	Lactobacillus	DSM 18302	May 24, 2006	ANIDRAL S.R.L.
	gasseri
47	Bifidobacterium	DSM 18350	Jun. 15, 2006	ANIDRAL S.R.L.
	adolescentis
48	Bifidobacterium	DSM 18351	Jun. 15, 2006	ANIDRAL S.R.L.
	adolescentis
49	Bifidobacterium	DSM 18352	Jun. 15, 2006	ANIDRAL S.R.L.
	adolescentis
50	Bifidobacterium	DSM 18353	Jun. 15, 2006	ANIDRAL S.R.L.
	catenulatum
51	Streptococcus	DSM 18613	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
52	Streptococcus	DSM 18614	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
53	Streptococcus	DSM 18615	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
54	Streptococcus	DSM 18616	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
55	Streptococcus	DSM 18617	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
56	Streptococcus	DSM 18618	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
57	Streptococcus	DSM 18619	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
58	Streptococcus	DSM 18620	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
59	Streptococcus	DSM 18621	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
60	Streptococcus	DSM 18622	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
61	Streptococcus	DSM 18623	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
62	Streptococcus	DSM 18624	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus
63	Streptococcus	DSM 18625	Sep. 13, 2006	MOFIN S.R.L.
	thermophilus

Claims

1. Solid form composition including: at least a biologically active substance selected from the group consisting of microorganisms; andat least a viscosizing agent selected from the group consisting of seed flours, carrageenans, alginic acid, alginates, and soluble food fibers.

2. (canceled)

3. Composition according to claim 1, wherein said soluble food fiber is selected from the group including: pectins, gums, depolymerized gums, galactomannans, glucomannans.

4. Composition according to claim 3, wherein said gum is selected from the group including natural gums and synthetic gums.

5. Composition according to claim 4, wherein said gum is selected from the group including: guar gum, tara gum, xantharean gum, xanthan gum, konjac gum, karaya gum, tragacanth, acacia, gellan gum.

6. Composition according to claim 1, wherein said viscosizing agent is selected from the group including: calcium alginate, tara gum, carrageenan and guar gum.

7. Composition according to claim 1, wherein the microorganism is selected from the group including microorganisms having a probiotic or symbiotic valence.

8. Composition according to claim 7, wherein said microorganism is selected from the group including the genera: Bifidobacterium, Lactobacillus, Leuconostoc, Lactococcus, Streptococcus, Pediococcus, Propionibacterium, Bacillus, Enterococcus, Saccharomyces.

9. Composition according to claim 8, wherein said microorganism is selected from the group including the species: Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus casei ssp. casei, Lactobacillus casei ssp. paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus delbrueckii ssp. lactis, Lactobacillus fermentum, Lactobacillus gasseri; Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium animalis, Bifidobacterium animalis ssp. lactis, Bifidobacterium adolescents, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum, Bifidobacterium infantis, Lactococcus lactis and Lactococcus lactis ssp. Lactis; S. thermophilus.

10. Composition according to claim 9, wherein the composition includes from one to six strain.

11. Composition according to claim 1, wherein said composition further includes at least a prebiotic fiber.

12. Composition according to claim 11, wherein said prebiotic fiber is selected from the group including: fructo-oligosaccharides (FOS); galacto-oligosaccharides (GOS); trans-galacto-oligosaccharides (TOS); xylo-oligosaccharides (XOS); chitosan-oligosaccharides (COS); α-galactoside selected from raffinose, stachyose; pectins; gums; partly hydrolized gums; inulin; psyllium; arabinogalactans; acacia, locust bean, oat, bamboo and citrus fibers.

13. Formulation including a composition according to claim 1 and a hydrophilic liquid medium.

14. Formulation according to claim 13, wherein the viscosizing agent is present in a higher or equal percentage than 0.05% (w/v), based on the final volume of the formulation.

15. Composition according to claim 1 wherein said composition is adapted for use as a medicament.

16-17. (canceled)

18. A method of treating an infective pathology of the rectum or vagina comprising the step of administering to a patient suffering from said infective pathology a pharmaceutically effective amount of a medicament comprising a composition according to claim 1.

19. Composition according to claim 9, wherein the composition includes four strains.

20. Formulation according to claim 13, wherein the viscosizing agent is present in a percentage between 0.2% and 20% (w/v), based on the final volume of the formulation.